Loading...
•
Sep 30, 2024
•/
Renalytix Q1 2025 Earnings Report
Renalytix's financial results for the fiscal year ended June 30, 2024, were updated.
Key Takeaways
Renalytix reported $2.3 million in revenue, including $2.1 million from testing services and $0.2 million from pharmaceutical services. The loss before tax was $44.9 million, which included impairment of intangibles of $10.2 million and fair value adjustments to convertible debt of $3.75 million. Total assets were $7.3 million, and cash and cash equivalents amounted to $4.7 million.
Total revenue reached $2.3 million.
Testing services generated $2.1 million in revenue.
Pharmaceutical services contributed $0.2 million in revenue.
Loss before tax was $44.9 million, impacted by impairment and fair value adjustments.
Renalytix
Renalytix
Renalytix Revenue by Segment
Revenue by Segment
Pharmaceutical Services Revenue
CapyFin.com